Search Results - "Hakes, T"

Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study by Francis, P, Rowinsky, E, Schneider, J, Hakes, T, Hoskins, W, Markman, M

“…This study was designed to define the maximum-tolerated dose (MTD) and pharmacology of paclitaxel administered by the intraperitoneal (IP) route on a weekly…”
Get more information

Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response by Seidman, A D, Reichman, B S, Crown, J P, Yao, T J, Currie, V, Hakes, T B, Hudis, C A, Gilewski, T A, Baselga, J, Forsythe, P

“…Two phase II clinical trials were performed to determine efficacy and tolerability of paclitaxel (Taxol; Bristol-Myers Squibb Co, Wallingford, CT) and…”
Get more information

Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer by Hudis, C A, Seidman, A D, Crown, J P, Balmaceda, C, Freilich, R, Gilewski, T A, Hakes, T B, Currie, V, Lebwohl, D E, Baselga, J, Raptis, G, Gollub, M, Robles, M, Bruno, R, Norton, L

“…Because docetaxel (Taxotere, RP 56976; Rhone-Poulenc Rorer, Antony, France) appeared to be active against breast cancer in phase I trials, we performed this…”
Get more information

Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer by Reichman, B S, Seidman, A D, Crown, J P, Heelan, R, Hakes, T B, Lebwohl, D E, Gilewski, T A, Surbone, A, Currie, V, Hudis, C A

“…A phase II study of Taxol (paclitaxel; Bristol-Myers Squibb Co, Princeton, NJ) as initial chemotherapy for metastatic breast cancer was conducted. Recombinant…”
Get more information

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin by Markman, M, Rothman, R, Hakes, T, Reichman, B, Hoskins, W, Rubin, S, Jones, W, Almadrones, L, Lewis, Jr, J L

“…In an effort to critically define the incidence and clinical characteristics of secondary responses to cisplatin-based therapy in patients with ovarian cancer…”
Get more information

Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer by Seidman, A D, Tiersten, A, Hudis, C, Gollub, M, Barrett, S, Yao, T J, Lepore, J, Gilewski, T, Currie, V, Crown, J

“…To evaluate the efficacy and safety of paclitaxel administered by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. Forty-nine…”
Get more information

Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer by Francis, P, Schneider, J, Hann, L, Balmaceda, C, Barakat, R, Phillips, M, Hakes, T

“…This phase II study was conducted to evaluate the efficacy and toxicity of docetaxel in the treatment of patients with platinum-refractory ovarian cancer…”
Get more information

Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study by Markman, M, Rowinsky, E, Hakes, T, Reichman, B, Jones, W, Lewis, Jr, J L, Rubin, S, Curtin, J, Barakat, R, Phillips, M

“…To evaluate the safety and pharmacology of the intraperitoneal (IP) administration of the antineoplastic agent taxol. Twenty-five pretreated patients who were…”
Get more information

Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer by Markman, M, Hakes, T, Barakat, R, Curtin, J, Almadrones, L, Hoskins, W

“…To examine the short-term and long-term results of paclitaxel therapy in patients with advanced heavily pretreated, cisplatin-refractory ovarian cancer. The…”
Get more information

Pain in ovarian cancer patients. Prevalence, characteristics, and associated symptoms by Portenoy, R K, Kornblith, A B, Wong, G, Vlamis, V, Lepore, J M, Loseth, D B, Hakes, T, Foley, K M, Hoskins, W J

“…The prevalence, characteristics, and impact of pain and other symptoms have not been studied systematically in women with ovarian cancer. Anecdotally, pain has…”
Get more information

Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin by Markman, M, Reichman, B, Hakes, T, Jones, W, Lewis, Jr, J L, Rubin, S, Almadrones, L, Hoskins, W

“…Phase II trials of second-line intraperitoneal (IP) cisplatin-based therapy in patients with ovarian cancer have demonstrated the ability of this approach to…”
Get more information

Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses by Fennelly, D, Schneider, J, Spriggs, D, Bengala, C, Hakes, T, Reich, L, Barakat, R, Curtin, J, Moore, M A, Hoskins, W

“…We commenced a phase I study of escalating dose Taxol (paclitaxel; Bristol-Myers Squibb Co, Wallingford, CT) in addition to cyclophosphamide, to assess its…”
Get more information

Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease by Markman, M, Hakes, T, Reichman, B, Lewis, Jr, J L, Rubin, S, Jones, W, Almadrones, L, Pizzuto, F, Hoskins, W

“…There is a critical need to find new antineoplastic drugs that are active in platinum-refractory ovarian cancer. We conducted a phase II trial of single-agent…”
Get more information

Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer by Seidman, A D, Norton, L, Reichman, B S, Crown, J P, Yao, T J, Heelan, R, Hakes, T B, Lebwohl, D E, Gilewski, T A, Surbone, A

“…Single-agent paclitaxel (TAXOL) was administered to 79 patients with stage IV breast cancer. Twenty-eight patients had no prior chemotherapy (for metastatic…”
Get more information

Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy by Rubin, S C, Hoskins, W J, Saigo, P E, Chapman, D, Hakes, T B, Markman, M, Reichman, B, Almadrones, L, Lewis, Jr, J L

“…Prior studies of the risk of recurrence following negative second-look laparotomy have included patients treated with a variety of chemotherapeutic regimens,…”
Get more information

A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer by Jain, K K, Casper, E S, Geller, N L, Hakes, T B, Kaufman, R J, Currie, V, Schwartz, W, Cassidy, C, Petroni, G R, Young, C W

“…Fifty-four patients with advanced breast cancer who had failed prior non-anthracycline combination chemotherapy were randomized to treatment with either…”
Get more information

Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials by Clarke, M, Collins, R, Darby, S, Davies, C, Elphinstone, P, Evans, V, Godwin, J, Gray, R, Hicks, C, James, S, MacKinnon, E, McGale, P, McHugh, T, Peto, R, Taylor, C, Wang, Y

“…In early breast cancer, variations in local treatment that substantially affect the risk of locoregional recurrence could also affect long-term breast cancer…”
Get full text

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials by Clarke, M, Collins, R, Darby, S, Davies, C

“…Quinquennial overviews (1985–2000) of the randomised trials in early breast cancer have assessed the 5 year and 10-year effects of various systemic adjuvant…”
Get full text

Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer by Markman, M, Reichman, B, Hakes, T, Lewis, Jr, J L, Jones, W, Rubin, S, Barakat, R, Curtin, J, Almadrones, L, Hoskins, W

“…To evaluate the impact on survival of the attainment of surgically defined favorable responses (S-R) to salvage intraperitoneal (IP) chemotherapy after initial…”
Get more information

Prognostic factors in advanced ovarian carcinoma by Redman, J R, Petroni, G R, Saigo, P E, Geller, N L, Hakes, T B

“…Nineteen factors were analyzed for prognostic significance in a series of 89 women with advanced (stage III or IV) ovarian carcinoma treated with chemotherapy…”
Get more information